<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01148667</url>
  </required_header>
  <id_info>
    <org_study_id>12/2006 1 531</org_study_id>
    <nct_id>NCT01148667</nct_id>
  </id_info>
  <brief_title>Lactobacillus Rhamnosus GG: Interaction With Human Microbiota and Immunity</brief_title>
  <official_title>Interaction of Orally Administered Lactobacillus Rhamnosus GG With Skin and Gut Microbiota and Humoral Immunity in Infants With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academy of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mead Johnson Nutrition</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Probiotics have been used as novel adjunct therapeutic approach in atopic
      dermatitis. In addition to balancing the gut microecology and promoting host immune defences,
      specific probiotics might further aid in controlling the microbial colonization of the skin,
      thereby reducing proneness to secondary infections which typically cause sustained symptoms.

      Thirty-nine infants with atopic dermatitis,randomized for a three-month-period in a
      double-blind design to receive extensively hydrolysed casein formula (NutramigenR,
      Mead-Johnson, USA) supplemented with (n=19) or without (n=20) Lactobacillus rhamnosus GG
      (ATCC 53103) 5.0 x 107 cfu/g to achieve a daily intake of 3.4 x 109 cfu.

      Sampling (blood and faecal samples, cotton swab from the skin) and clinical examination of
      the infant, including SCORAD assessment to determine the severity of atopic dermatitis, at
      each study visit (at entry and one month and three months thereafter).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>severity of atopic dermatitis</measure>
    <time_frame>March 2007 - July 2008</time_frame>
    <description>Severity of atopic dermatitis of the study infants will be assessed by SCORAD index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maturation of humoral immune responses</measure>
    <time_frame>March 2007 - July 2008</time_frame>
    <description>Determination of proportions of immunoglobulin secreting cells among peripheral blood mononuclear cells was carried out by ELISPOT assay. The proportions of CD 19+ memory B cells was carried out by flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Gut Microbiota</condition>
  <condition>Skin Microbiota</condition>
  <condition>Humoral Immune Responses</condition>
  <condition>Severity of Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Infants drink formula added with LGG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants have been randomized (1:1) to get casein hydrolysate with or without LGG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants drink casein hydrolysate without LGG</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infants get extensively hydrolysed casein formula</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Casein hydrolysate added with LGG</intervention_name>
    <description>Infants drink extensively hydrolysed casein formula supplemented with LGG (ATCC 53103) 5.0 x 10 7 cfu/g to achieve a daily intake of 3.4 10 9 cfu.</description>
    <arm_group_label>Infants drink formula added with LGG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Infants drink casein hydrolysate without LGG</intervention_name>
    <description>Infants drink extensively hydrolysed casein formula without added LGG</description>
    <arm_group_label>Infants drink casein hydrolysate without LGG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of atopic dermatitis

          -  age 4 we - 18 mo

        Exclusion Criteria:

          -  skin infection or severe infection at the time of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Turku University Central Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2010</study_first_submitted>
  <study_first_submitted_qc>June 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <last_update_submitted>June 21, 2010</last_update_submitted>
  <last_update_submitted_qc>June 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Erika Isolauri</name_title>
    <organization>University of Turku</organization>
  </responsible_party>
  <keyword>atopic dermatitis</keyword>
  <keyword>barrier function</keyword>
  <keyword>gut</keyword>
  <keyword>probiotics</keyword>
  <keyword>skin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caseins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

